

251 North Avenue West, 2nd Floor
Westfield, NJ 07090

Mayer, Fortkort & Williams, PC
Attorneys At Law

Fax

OFFICIAL

FAX RECEIVED
JAN 27 2003
GROUP 1600

To: Assistant Commissioner for Patents

From: David Bonham
(703) 433-0510

Fax: 703-672-9306

Total pages: 18

Phone:

Date: 1/24/03

Re: In connection with prosecution in Serial. No.
09/845,080, please find enclosed an Amendment and **CC:**
Response to the Office Action of October 24, 2002.

Sincerely,

David Bonham

☐ **Urgent** ☐ **For Review** ☐ **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

PRIVACY AND CONFIDENTIALITY NOTICE

The information contained in this communication is confidential and may be legally privileged. It is intended solely for the use of the individual or entity to whom it is addressed and others authorized to receive it. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this information is strictly prohibited.

If you received this communication in error, please immediately notify us by a collect telephone call to the writer and return the original message and documents to us at the above address via the United States postal service.

#10/A
B
1-30-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Naimark et al.
Serial No.: 09/845,080
Filed: April 27, 2001
Title: MICROPARTICLE PROTECTION
OF THERAPEUTIC AGENTS
Art Unit: 1632
Examiner: Dave Trong Nguyen
Docket No.: 00-0238

VIA FACSIMILE 703-872-9306
Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND RESPONSE

Sir:

In response to the Office Action mailed October 24, 2002 in the above matter,
please enter the following amendments and remarks.

IN THE CLAIMS:

Please delete claims 6, 16 and 18-36 without prejudice or disclaimer.

Please amend claims 1, 2, 4, 7-12 and 17 as follows:

-
1. (Amended) A method of using polymer microparticles to protect pharmaceutical effectiveness of a pharmaceutically active agent comprising:
- providing a pharmaceutically acceptable suspension comprising a pharmaceutically active agent and polymer microparticles, wherein said pharmaceutically

A1